Journal of Integrative Oncology

ISSN: 2329-6771

Open Access

Current Issue

Volume 9, Issue 1 (2020)

    Editorial Pages: 1 - 1

    Oncology 2020 conference scheduled at Paris, France during February 20-21, 2020

    Abdalla Abotaleb

    Hilaris Conferences feel delighted to announce our forthcoming event “ONCOLOGY 2020” which is going to be held during February 20-21, 2020 in Paris, France with the theme “Fearless commitment for a Cancer free world”.

    Editorial Note Pages: 1 - 1

    Editorial Note on Journal of Integrative Oncology

    Annabel Rose

    Journal of Integrative Oncology (JIO) is an open access, peer reviewed scientific journal which believes to promote and publishes novel findings in the subject area of Cancer Biology, Integrative Medicine, Stem Cell Research, Immunology, Chemotherapy etc. and its related field.

    Cancer Treatment and Prevention (2020)

      Value Added Abstracts Pages: 1 - 1

      Global Summit On Oncology and Breast Cancer | March 05-06, 2020 | Vienna, Austria

      N. Senhou

      DOI: 10.37421/jio.2020.S1.01


       We’re pleased to bring you exciting news about next year’s “Global Summit On Oncology and Breast Cancer ”.Which is going to held on March 05-06, 2020 | Vienna, Austria . We have set a date and location that we hope for the foundation of a productive and enjoyable gathering.

      Oncology 2020 regards each one of the individuals to go to the “Oncology 2020” amidst March 05-06, 2020. which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops, Speaker sessions.

      Oncology 2020 will join world-class professors, scien­tists, researchers, students, Perfusionists, Oncologists to discuss methodology for ailment remediation for Cancer diseases, Breast Cancer and health disorders. Oncology 2020 are planned to give various information that will keep helpful specialists next to each other of the issues impacting the expectations, finding and treatment of Cancer diseases. The assembling of this event will be dealt with around the subject “Oncology 2020”.

      Value Added Abstracts Pages: 2 - 2

      Beam Quality Measurement and Verification in Radiation Therapy

      Barrington Brevitt

      DOI: 10.37421/jio.2020.S1.002

      The aim of all radiotherapy treatment is to precisely deliver a prescribed dose of radiation to a tumour volume while simultaneously sparing the organs at risk (OARs) surrounding this tumour. Radiation therapy has evolved and the method of radiation generation varies, ranging from the controlled emission of gamma rays from a Cobalt 60 source to the production of particles such as; photons, electrons and protons produced in linear accelerators. The high energy photons employed during tumour treatment can interact with components of the gantry such as lead jaws, and produce particles that may contaminate the treatment beam. These contaminants are produced through various interactions with the photons and the absorbing medium such as; Compton Interaction, Photoelectric Effect and Pair Production. Photons have more penetrating power than charged particles of similar energy, and as they traverse a medium there is energy transformation to electron energy(1). The prospect of an interaction per unit distance travelled is denoted by the principle N= N_0 e^(-μx), where μ is dependent on the energy of the photon and the materials through which it travels(2). The aim of this paper is to conduct beam quality measurements and verification for treatment plan quality assurance in radiation therapy. An IBA Pharma type ion chamber (FC65-G) and electrometer (IBA Dose 2) were used to obtain ionization charges for an 18MV and a 6MV photon beam from a C-Series linear accelerator. These measurements were taken using a 1D water phantom, dimensions 40cm* 35cm*34.5 cm at a source to detector distance (SDD) of 100cm with the chamber 10cm beneath the water surface. The “K” (quality conversion factor) was calculated using the TPR20, 10 method. Two sets of measurements were taken at a depth of 20 cm and 10 cm beneath the water surface at a source to detector distance of 100cm. Three measurements were taken for both photon energies at polarities of +300, -300 and +100 on the electrometer. Ka values were calculated using the TPR20, 10 principles outlined in the TRS 135 protocol. The Ka value for the 6MV photon was determined to be 0.996 Gy while that for the 18MV was 0.973 Gy. These Ka values were then used to determine the tabulated percentage depth dose (PDD) for the photon energies. The tabulated PDD’s were 0.665 and 0.788 for the 6MV and 18MV beam respectively. From equation 2, Dw (10cm) for 6MV photon was calculated to be 0.68 Gy and that for the 18 MV photon was 0.81 Gy. The absorbed dose of the treatment unit at Dmax (Eq. 3) was calculated to be; (18MV) 1.03 Gy and (6MV) 1.03 Gy

      Value Added Abstracts Pages: 3 - 3

      The Male Breast Cancer Coalition (MBCC).

      Cheri ambrose

      DOI: 10.37421/jio.2020.S1.003

      February 13, 2019 marked the 5th anniversary of The Male Breast Cancer Coalition (MBCC).  This non-profit and awareness foundation was established with the objectives of saving lives through advocacy, education and a complete resource access of any and all support facilities and clinical information leading to the diagnosis, treatment and prevention of Male Breast Cancer. Origins of the MBCC came from the partnership between MBCC President and Co-founder, Cheri Ambrose of New Jersey and co-founder Bret Miller of Kansas City who is recorded as the youngest male worldwide to contract breast cancer. Bret was just 17 years old when he found a lump during a high school sports physical. For six years he was told by various doctors that it was nothing to worry about, just calcium that would dissipate as he got older. Bret underwent a mastectomy for breast cancer at the age of 24.  He promised his doctor that if cured, he would become the face of breast cancer for me. He started his own awareness foundation, the Bret Miller 1T Foundation with his mother Peggy Miller as his manager and was attending many of the local 5k races and breast cancer events in Kansas City in an effort to bring awareness to the risk men face. Cheri had been working at her own organization in New Jersey known as the Blue Wave.  The Blue Wave was born out of a need for awareness after a very dear friend had been diagnosed with breast cancer.  He went from being a vibrant, outgoing person into a virtual hermit, shutting himself off from everyone due to embarrassment of having a women’s disease. Once connecting, through social media and an hour-long phone call with Peggy Miller, Bret’s mother and foundation manager, the two knew there was so much more they could do together and joined forces and never looked back.  To date touching the lives of over 500 men diagnosed with breast cancer around the world.

      Value Added Abstracts Pages: 4 - 4

      Efficacy of oral immunotherapy in a case of metastatic breast cancer.

      Tarang Krishna

      DOI: 10.37421/jio.2020.S1.004

      Breast cancer is one of the most common cancers in women. World Health Organization estimated the number of diagnosed breast cancer cases at approximately 2.1 million in 2018. This equals to about 11.6% of the total cancer incidence burden1. Globally, the incidence rates of breast cancer are much higher as compared to other cancers. Such high prevalence of breast cancer calls for an effective treatment that is able to resolve the condition permanently. Although the best form of resolution is early diagnosis but an assured treatment should be sought as most of the cases get detected in advanced stages. The potential side effects of chemotherapy and radiotherapy make them a non viable option in the treatment of breast cancer. The treatments of hormone therapy and targeted therapy are also not devoid of side effects. The treatment should be such that relieves the ailment of the patient rather than augmenting it. Another form of treatment that has emerged to treat various forms of cancer including breast cancer is immunotherapy and it is still in the stage of clinical trials. Many studies have been conducted in relation to the treatment of metastatic breast cancer with immunotherapy but none has been plausible in removing the disease entirely from the body and the possibility of emergence of alternate effects has also not been entirely ruled out. This case report aims to establish the efficacy of oral immunotherapy treatment in a patient of metastatic breast cancer in terms of the following: 1) Relieving the patient of her presenting complaints. 2) Removing the evidence of the disease completely from the body. 3) Ruling out relapse of the disease. 4) Ensuring a normal life to the patient.

      Value Added Abstracts Pages: 5 - 5


      Karimova N.S

      DOI: 10.37421/jio.2020.S1.005

      Summary. In biopsy preparations, there are 30 patients with cervical cancer at the IIb-IIIb clinical stages. A study in patients with locally advanced cervical cancer showed that a high expression level of Ki67 proliferation in primary patients, elevated levels of p53 protein before carrying out correlate with an unfavorable prognosis, which makes it possible to use these indicators in monitoring the course of the disease. It was shown that prior to the initiation of antitumor treatment, the expression level of Ki67 was as high as possible in those patients who subsequently showed progression of the disease, and reached 85%. The expression level of Ki67 and p53 protein was shown to correlate with indicators of tumor progression. The aim of the study was:  In accordance with the purpose of the study outlined above, the expression level of molecular biological markers Ki67, Bcl2, p53 and their prognostic value in patients with locally advanced cervical cancer who received complex treatment were assessed. Material and methods: 30 patients with locally advanced cervical cancer with IIB – IIIA-B stage who received chemoradiotherapy in ССncer center from 2014 to 2017 were examined. The stages of the disease before the start of treatment were carried out in accordance with the international classification of TNM (seventh revision 2009) and in accordance with the classification of the International Federation of Obstetricians-Gynecologists classification (FIGO, 2011). The diagnosis of the disease in all cases verified histological. Morphologically, all women were diagnosed with squamous cell carcinoma. The possibilities of the proliferative activity marker Ki67, p53 protein, Bcl2 in determining the prognosis of the disease, locally advanced cervical cancer were studied. The material of the study was cervical

      All patients underwent 3 courses of neoadjuvant polychemotherapy with 21 day intervals, according to the scheme: Cisplatin 100 mg 1 day, Fluorouracil 1000 mg 1-4 days.Then, after computerized topometry of the pelvic organs, planning of combined radiation therapy was carried out, including remote gamma therapy and intracavitary brachytherapy. Remote irradiation was carried out on a gamma therapeutic apparatus (TERABALT type 80 model SCS 2012 Czech Republic) in the standard fractionation mode (daily 5 times a week Single Focal Dose 2 Gy to Total Focal Dose 46 Gy). Intracavitary radiotherapy was performed on a BEBIG brachytherapy device - MULTISOURSE Co60 2013. (Germany) in fractional mode Single Focal Dose 5 Gy, eq Total Focal Dose to point A up to 70-90 Gy, to point B 50-58 Gy. The initial expression of the listed immunohistochemical markers in the tumor and prior to chemo-radiotherapy was evaluated. The immunohistochemical study was carried out according to a standard procedure on dewaxed sections of cervical tissue blocks obtained from resection specimens or cervical biopsies. A pathologist to clarify the histological diagnosis and the correspondence of the blocks to the selected sections reviewed all drugs.

      Value Added Abstracts Pages: 6 - 6

      Gut microbiota behavior, low carbohydrate dietary intake and cancer.

      Leo Nissola

      DOI: 10.37421/jio.2020.S1.006

      Gut microbiota is a key intermediary between diet and host physiology, modulating several metabolic and neurological signaling pathways. Microbiota plays a key role in digestion, metabolism and behavior as well as microbial response to diet. Dysbiosis of gut microbiota has been strongly related to cancer. Ketogenic diet alters the gut microbiota and protects against multiple chronicle diseases and recent studies have linked ketogenic diet with cancer prevention. It is known that over 30 percent of all cancers can be prevented by lifestyle and dietary measures. Obesity, nutrient sparse foods such as concentrated sugars and refined flour products impairs the glucose metabolism. The hypothesis that cytotoxicity induced by glucose deprivation in cancer cells is mediated by mitochondrial superoxide and H2O2 was confirmed by exposing glucose-deprived transformed human fibroblasts to electron transport chain blockers (ETCBs), known to increase mitochondrial superoxide and H2O2 production by a wide number of researchers. Therefore, glucose deprivation in the presence of ETCBs enhanced oxidative stress as well as cell death in several different human cancer cell lines (PC-3, DU145, MDA-MB231, and HT-29). Low fiber intake, consumption of red meat, and imbalance of omega 3 and omega 6 fats contribute to an increase in overall cancer risk in both genders. Studies have show that when a diet is well balanced, it is likely that there would be at least a 60 percent decrease in breast, colorectal, and prostate cancers. Improving metabolites and immunological

      anticancer profile by k-PBD. There’s robust evidence that shows prolonged fasting, fastingmimicking diet (FMD) and ketogenic diet demonstrates a strong usefulness as adjuvants in cancer therapy.

      Value Added Abstracts Pages: 7 - 7

      Evaluation of predictors for behavioral intentions to adhere to cervical cancer treatment among aged 25-49 years in Botswana.

      Major, T.E., Koyabe, B., Ntsayagae, E., Molwane, B., and Monare, B

      DOI: 10.37421/jio.2020.S1.007

      There is evidence of ongoing research and investment in Africa to improve vaccination, screening, and treatment for cervical cancer (Finocchario-Kessler , Wexler , Maloba , Mabachi , Ndikum-Moffor , Bukusi; 2016). However, the majority (54.6 %) of cervical cancer research in Africa focused on secondary prevention (i.e., screening). This is followed by studies focusing on primary prevention (23.4 %) of cervical cancer, particularly HPV vaccination. Finocchario-Kessler, etc (2016) records that research focusing on tertiary prevention, which is the treatment of cervical cancer, is at the lowest (17.6 %). It is vital that research focusing on tertiary prevention for women diagnosed with abnormal cervical tissue is given equal attention as a matter of urgency for the overall survival (OS) for women with locally advanced cervical cancer. Studies on adherence to treatment regimen and schedule for cervical cancer will inform the innovation and improvement efforts towards treatment adherence and follow-up of women diagnosed with abnormal cervical tissue.

      Value Added Abstracts Pages: 8 - 8

      Role of Vitronectin as a potential Serum Biomarker for Breast Cancer Prognosis

      Meera Srivastava*, Alakesh Bera

      DOI: 10.37421/jio.2020.S1.008

      Introduction: Breast Cancer is the most common form of cancer in women worldwide, impacting nearly 2.1 million women each year. In 2018, nearly 627,000 women died of breast cancer, which accounts for 15% of all cancer deaths. Identification of new biomarkers could be key for early diagnosis and therefore, increase the survival.  Vitronectin, a glycoprotein that is abundantly found in serum, extracellular matrix, and bone, binds to integrin alpha V beta 3, and promotes cell adhesion and migration. Current studies indicate that patients with amplified Vitronectin copy-number have lower survival rates than patients without amplified Vitronectin. In this study, we focused on the role of vitronectin in breast cancer survival and its functional role as a non-invasive biomarker for early stage and stage specific breast cancer detection. Materials and Methods: To confirm that the expression of vitronectin is amplified in breast cancer, a total of 240 serum samples (n=240) from breast cancer patients were analyzed using the Reverse Phase Protein Array (RPPA) technique. Of the 240 samples, 120 samples were of African American descent, while the other 120 were of Caucasian American descent.

      Value Added Abstracts Pages: 9 - 9

      Breast cancer risk factors, prevention and patients empowerment

      Míriam Algueró Josa

      DOI: 10.37421/jio.2020.S1.009

      Breast cancer was the most common cancer in women worldwide in 2018, contributing 25.4% of the total number of cases diagnosed. Evidence says that less than 10% (between 6% and 7%) of the total is due to genetic missfailiures. Some mutations, particularly in BRCA1, BRCA2 and p53 might induce an increase of breast cancer. However, these mutations are rare and account for a small portion of the total breast cancer burden. (1) Risk factors Lifestyle is also determinant when it comes to cancer. Several researches have proven that unhealty diets, obesity (2), smoking (3), alchool intake (4) and a sedentary life style (5) might translate in an increase of all types of cancer risk, including breast cancer (6) Breast cancer prevention According to reserch there are several things that patients can do to prevent all types of cancer, including breast cancer (7),(8), (9) Patient empowerment Research has shown that a healthy lifestyle increases chances to overcome breast cancer. Passing this information on to patients is crucial for them to take an active part in their illness and improve their quality of live as well as their chances to recover health. (10)

      Value Added Abstracts Pages: 10 - 10

      Radiation protection during PRRT therapy in NGHA

      N. Senhou

      DOI: 10.37421/jio.2020.S1.010

      Radiation protection in medicine covers in principle, medical exposure, occupational exposure, and public exposure in association with various clinical circumstances. Medical exposure involves not only patients but also their relatives and medical staff. Peptide receptor radionuclide therapy (PRRT) is a molecular targeted therapy used to treat neuroendocrine tumors (NET). In National Guard Hospital in Saudi Arabia the PRRT therapy is kind of new treatment and the radioprotection for such treatment was unknown because of the lack of reference or lectures, in some cases it may be considered as a low contamination treatment because it’s a beta emission, PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects, Therapeutic procedures with beta emitters are growing. The purpose of this topic is to report on the current state of PRRT, to clarify the issues of radiation protection associated with PRRT, and to show future prospects. Medical staff is often not aware of the high risk of exposure to beta radiation, inappropriate dose meters available or used can make it more complicated, the

      personal dose meters used often are not worn properly. Skin dose of staff during labelling(preparation) and infusion (administration) should be done carefully because extremity exposure of technicians during preparation may exceed dose limit if safety standards are not strictly kept. PRRT requires deliberate radiation protection standards as it uses unsealed radionuclides and gives therapeutic radiation doses in humans. the goal of this topic is the proposal of large variations of individual practices during preparation and administration and to imply options for improving radiation safety

      Value Added Abstracts Pages: 11 - 11

      Knowledge on colorectal cancer prevention among adults attending at a tertiary level hospital

      Sachita Budhathoki, J.Pokharel

      DOI: 10.37421/jio.2020.S1.011

      Colorectal cancer ranks among the third most common cancer worldwide, second in terms of mortality due to cancer and has shown an increasing trend of incidence in Asian region lately.    In Nepal, It is among the top five most common cancers in both males and females. Over the next ten years, countries in the low- income Asia pacific region including Nepal are projected to have the highest colorectal cancer  growth rates of 70%. Owing to the growing burden, there is demand for more research in the field and hence strategies to increase the knowledge on colorectal cancer. The American cancer society asserts that colorectal cancer is common after age 50 and its screening should start after age 45. This study aimed to assess the level of knowledge on colorectal cancer including knowledge on preventive lifestyle and screening tests among adults. A cross sectional descriptive study was conducted from 2018 october- 2019 January among 110 non- cancer patients and adults aged 40-75 years attending Nepal Medical college Teaching Hospital. Non-probability purposive sampling was done. Structured interview questionnaire adopted from standard bowel cancer awareness measure (CAM) developed by cancer research UK was used for data collection. Frequency distribution, mean values and chi-square value were computed for statistical analysis. Results show that 81.8% had heard of colorectal cancer in their lifetime while 18.2% had never heard of it before. The main source of information was friends (47.7%)  Of those who had heard of colorectal cancer, 92.2% believed colorectal cancer is preventable while 23.3% had in fact heard about colorectal cancer screening tests and mean knowledge percentage on the domain was only 14.44%. Mean knowledge percentage was found highest (74.6%) for knowledge regarding preventive lifestyle practices. Majority (65.6%) had moderate level of knowledge, 24.4% had inadequate knowledge while only 10% had adequate level of knowledge. Significant statistical association was

      not found between level of knowledge and selected demographic variables like age, sex, education, occupation (p<0.05) There is need of extensive public awareness programs on colorectal cancer with a focus on screening tests to fill the gaps of knowledge and promote utilization of early screening methods for prevention. Health care professional should be able to provide planned, structured health teaching on colorectal cancer to disseminate authentic information on the topic.

      Value Added Abstracts Pages: 12 - 12

      Effect of Topical Anesthetic Cream on Pain During Periareolar Injection of Technetium Tc99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer: A Randomized Control Trial

      Sarah Canning

      DOI: 10.37421/jio.2020.S1.012

      Background: Injection of Tc99m to localize nodes for sentinel lymph node biopsy is reported by patients as very painful. The purpose of this study was to determine if anesthetic cream reduces pain associated with periareolar injection of Tc99m and to help elucidate conflicting literature regarding the efficacy of anesthetic cream for this procedure. Methods: A randomized, double-blind, placebo-controlled methodology was used for adult females with breast cancer undergoing periareolar injection of Tc99m for sentinel lymph node biopsy. Pain levels were compared using anesthetic cream (2.5% lidocaine/2.5% prilocaine) vs. placebo. Patient exclusion criteria included use of opioids or adjuvant pain medication or injecting Tc99m the day before surgery. The Numerical Rating Scale was used to assess pain levels immediately after the injections. Results: Comparing 23 experimental and 26 control pa

      tients, there was no significant difference between the experimental (median = 4) and the control group (median = 5) on level of pain experienced U=0.492, P > .05. Conclusions: The experimental group had a slightly lower median pain score; however, there was no statistically significant difference between those who used the cream compared with those who used a placebo, supporting the conclusion that anesthetic cream does not reduce pain during Tc99m injections. This study adds to the current literature to provide a stronger position that there is no benefit to using anesthetic cream for this procedure.

      Value Added Abstracts Pages: 13 - 13

      Increasing Risk of Breast Cancer in IVF Cases

      Dariush D. Farhud

      DOI: 10.37421/jio.2020.S1.013

      the increase rate of infertility, the referral rate to infertility treatment centers has also increased. Nowadays, assisted reproductive technology (ART) is used to treat this problem. Considering the possible future implications for mothers who are treated with in-vitro fertilization (IVF) and the offspring as the end product of this method, extensive researches have been conducted in this regard. According to some researches, there is speculation about the increased risk of cancer in mothers and their offspring. In in-vitro fertilization (IVF), drugs such as Clomiphene citrate and gonadotropins are used to stimulate and mature follicles and thus increase ovulation. Based on studies, the long-term use of these drugs can increase estrogen hormones and cause excessive expression of genes, resulting in an increased risk of breast cancer. Breast cancer is one of the most common cancers among women, which is mostly hereditary and afflicted with high and growing severity. In this article, we are referring to and collecting more than one hundred articles worldwide, which followed the hypothesis that the use of IVF drugs can lead to breast cancer, and our findings completely confirm this. With this in mind, mothers who are going to have infertility treatments should be individually evaluated “personalized medicine” and family history of breast cancer, must be considered prior to treatment.

      Value Added Abstracts Pages: 14 - 14

      The T cell Repertoire as a biomarker for breast cancer detection

      Miri Gordin and Hagit Philip

      DOI: 10.37421/jio.2020.S1.014

      To study the T-cell repertoire during tumor progression, we followed 10 female mice of a transgenic mouse strain that expresses the un-activated rat neu (Erbb2) oncogene, along with 5 control mice. These mice develop mammary tumors spontaneously over 5-8 months. To quantify the peripheral T cell repertoire, we extracted T cells from blood, every month, over the period of 9 months. Cells from these samples were sorted and later processed through a cDNA TCR С and С library preparation protocol using single-molecule barcoding and then NGS sequenced. We were able to use the repertoire to classify tumor and non-tumor mice, using their immunological repertoire. Using feature selection algorithms, we were able to provide superior classification using a small subset (3 to 6 clones) of the T cell repertoire. Thus, machine learning

      and feature selection allowed us to reduce the hundreds of thousands of TCR alpha and beta sequences obtained during repertoire sequencing, to a set of six clones, with which we can identify the source of a blood sample as tumor or control. We can further stratify older transgenic mice (older than 5 months) and those of older control mice, using the same small T cell clones’ subset. This latter classification has been obtained with as little as three T cell clones.

      Value Added Abstracts Pages: 15 - 15

      Health Beliefs on the Behavioral Adoption of Mammography Screening: A Path Analytic Model

      Soo Foon Moey

      DOI: 10.37421/jio.2020.S1.015

      Despite the effectiveness of mammography for early breast cancer detection, its’ utilization among Malaysian women remains low. This is possibly due to mammography screening being still opportunistic in nature. Conceptualizing screening behavior intentions utilizing Health Belief Model (HBM) is appropriate in understanding behavioral changes. As such, the study utilized HBM constructs in predicting the variance in adaptive behavior of mammography while controlling for moderating effects of knowledge and socio-demographic factors and mediating effects of self-efficacy using structural modeling fit analysis. Materials and methods A multi-stage, stratified random sampling method was utilized to select the polyclinics in Kuantan, Pahang. Five hundred and twenty Malaysian women aged between 35 and 70 years were selected randomly using sample size calculation at 5% type 1 error, p < 0.05, absolute error at 2%.  Sets of the copyrighted, validated questionnaire were used to obtain the data. Structural equation modeling using Mplus was used to test the model. Indirect effects were included iteratively to the path model for evaluating moderating and mediating effects significance.

    Relevant Topics


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward